China Tracker - Details for Tianyin Pharmaceutical (TPI)

 Tianyin Pharmaceutical
Shares Outstanding (MRQ): 30.52 mill 
New Shares / Dilution (TTM): 0.08 mill0.28%
New Shares / Dilution (since Dec 31, 2008): 14.83 mill94.53% 
Cash (MRQ): 31.17 mill0.00%
Account Receivables (MRQ): 9.40 mill0.00%
Account Receivables (Q/Q): + 0.22 mill2.44% 
Long-Term Debt (MRQ): NO DEBT
Revenue Growth (Q/Q): 15.41% 
Revenue Growth (Y/Y): 69.61%
Net Income Growth (Q/Q): 19.66% 
Net Income Growth (Y/Y): 71.35%
EPS Growth (Y/Y): 70.88%
Net Margin (Q/Q): 17.4% (16.8%)0.60% 
Net Margin (Y/Y): 17.4% (17.2%)0.20% 
EPS | P/E (2 MRQ Projection): $0.530.00 
CFPS | P/CF (2 MRQ Projection): $0.710.00 
Price/Sales (2 MRQ Projection): 0.00
Price/Book (MRQ): 0.00 
Auditor: Patrizio & Zhao
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2010-10-31): $0.650.00 
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2008-01-16 
Uplisting to Senior Exchange: on 2008-10-03 at $2.05 (-100.00% since Uplisting)

 Business Outlook

Due to the recent healthcare reform and the resulting pricing pressure on generic pharmaceutical sales nationwide, since January 2011, our generic division which makes up approximately 40% of our total revenue is expected to experience sales reduction for the next few quarters. In addition, the longer than expected equipment installation and GMP certification preparation process following the newly issued SFDA GMP standards by the PRC government at the beginning of March 2011, are expected to reduce the previously forecast revenue of JCM macrolide facility. We therefore revise our fiscal year 2011 revenue guidance to $90.0 million representing 40.8% year over year growth, from the previously guided $113.0 million in total revenue.

Based on the revised revenue forecast of $90.0 million along with the new 25% income tax rate starting in January 2011 from the previous 15% for Chengdu Tianyin, we revise our net income forecast to $16 million, representing 32.9% year over year growth from previous $18 million. The forecasted net income excludes any non-cash expenses associated with stock compensation plans or stock option expenses. Our analysis of the market condition suggests that although the pricing pressure on the generic division is likely to continue for the remainder of 2012 calendar year, the JCM along with TMT distribution business are expected to support the growth of TPI for the coming fiscal year.

(Source: PR Newswire, 2011-05-16)

Jiangchuan focuses on the production of one of the world's best-selling antibiotics, macrolide antibiotics, such as Azithromycin. Jiangchuan holds a license from China's SFDA to produce macrolide antibiotics and a related business license from the Industry and Commerce Bureau and Tax department. Tianyin owns 77% of Jiangchuan and will utilize Jianchuan as the foundation of a broader, longer term strategy to build a significant presence in the rapidly growing macrolide antibiotics market. Construction of the new production facility in Xinjin Industrial Development Area commenced on January 8, 2010 with Phase I capacity of 240 ton capacity, followed by Phase II (total of 480 ton capacity including phase I) with a total estimated capital expenditures of $20 million. Tianyin anticipates Jiangchuan's revenue contribution to begin in the 2nd half of fiscal year 2011.

Since the inception of Tianyin Medicine Trading (TMT), we have been developing the distribution portfolio of TMT, Tianyin's distribution arm for specialty products manufactured by other pharmaceuticals that provide synergy to our existing organic product portfolio. Previously, TMT distributes mainly Tianyin's own products. In early November this year, we have successfully obtained one year distribution rights from state-owned Jiangsu Lianshui Pharmaceutical (Lianshui) to distribute approximately 15 Lianshui-branded generic injection products including cough suppressant, antiobiotics along with other healthcare indications. We forecast the annual distribution revenue from TMT to reach approximately $10 million.

(Source: PR Newswire, 2010-11-10)

The management reaffirms FY2011 revenue guidance of $113.0 million and net income guidance of $18.0 million, representing 77.0% and 50.0% year over year growth respectively.

(Source: PR Newswire, 2010-09-29)

    see all Business Outlook notes

 Investor Presentations
2010-09-23 (PDF)   DOWNLOAD (right click, save as)
2010-06-03 (PDF)   DOWNLOAD (right click, save as)
TPI
Healthcare & Drugs
SCORE
6
READ: Score Cards Explained
SAFETY/RISK SCORE
MODERATE RISK
DETAILS: Safety/Risk Model for TPI
Current Price:  n/a
F10k Day (2008-05-14): -100.00%$3.60
2009 Close: -100.00%$4.17
2010 Close: -100.00%$2.72
2011 Close: -100.00%$0.59
High (2012-03-20): -100.00%$0.89
Low (2012-06-20): -100.00%$0.25
Exchange:
Market Capitalization: n/a
Total Shares: 30.52 mill
Float: n/a
Avg Volume: 120.50 k
Short Interest: 20.10 k
Short Ratio: 0.13%0.2 d
Last Quarter: 2010-12-31
Revenue (MRQ): 25.33 mill
Net Income (MRQ): 4.40 mill
Op. Cash Flow (MRQ): 12.89 mill
all financial data provided without warranty